AstraZeneca's Gout Dilemma: Should Smaller, More Frequent Lesinurad Dose Be Studied?
Executive Summary
FDA is concerned about product's narrow therapeutic index, but advisory committee says it’s not an issue for approval; could this be addressed in post-marketing trial?
You may also be interested in...
AstraZeneca’s Gout Drug Lesinurad Hobbled By Renal Risk
Lower dose of oral, uric acid transporter inhibitor shows good efficacy in two of three Phase III trials, but renal safety risk appears to limit lesinurad’s potential market – if it gets approved at all.
AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate
The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.